Can i snort oxycodone hydrochloride

The sooner you seek treatment, the greater the chances for a successful long-term recovery. She has always had a passion for literature and the written word. Upon graduation, Jena found her purpose in educating the public on addiction and helping those that struggle with substance dependency find the best treatment options available.

All of the information on this page has been reviewed and verified by a certified addiction professional. Theresa is also a Certified Professional Life Coach and volunteers at a local mental health facility helping individuals who struggle with homelessness and addiction. Theresa is a well-rounded clinician with experience working as a Primary Addiction Counselor, Case Manager and Director of Utilization Review in various treatment centers for addiction and mental health in Florida, Minnesota, and Colorado.

She also has experience with admissions, marketing, and outreach. As a proud recovering addict herself, Theresa understands first-hand the struggles of addiction. There is no limit to what Theresa is willing to do to make a difference in the field of Addiction! Northridge, CA. Tarzana, CA. Los Angeles, CA. Malibu, CA. Huntington Beach, CA. Fountain Valley, CA. Santa Ana, CA. Costa Mesa, CA. Irvine, CA. Newport Beach, CA.

Laguna Hills, CA. Lake Arrowhead, CA. Dana Point, CA. In reality, when drugs are snorted they must pass through the nose, to the heart and lungs, then onto the rest of the body. Whereas when someone smokes the drug, it goes straight to the lungs. The issue with snorting is that the nose is not designed to absorb that many powders, it is designed to filter out particles that should not be in the body. With repeated abuse, the mucous membrane can become worn down and damaged. When oxycodone is snorted, side effects of the drug can include sudden, a dangerous drop in blood pressure, seizures, slowed breathing, cardiac arrest, and potential death.

Some additional effects of oxycodone may include:. After long-term misuse of oxycodone, individuals can experience a dangerously decreased level of testosterone. Other long-term effects of oxycodone include excessive sweating, swelling in the arms and legs and chronic constipation. One study showed that individuals can suffer from nasopharyngeal necrosis after chronically snorting oxycodone.

This condition is associated with severe tissue destruction, causing a defect in the soft palate roof of the mouth. Long-term misuse of oxycodone can also result in immunosuppression or a general weakening of the immune system.

Possible effects of opioid-induced immunosuppression have been reported to include susceptibility to infection, increased risk of cancer, and an increased risk of HIV infection in drug abusers. Chronic use of oxycodone will also lead to tolerance and dependence and when someone suddenly stops using they will be subject to intense withdrawal symptoms. These symptoms can include central nervous system CNS hyperactivity that will peak 48 to 72 hours after the last dose of the drug. Withdrawal from oxycodone will begin with feelings of restlessness and anxiety followed by an increased breathing rate, runny nose, stomach cramps, excessive tearing and sweating, and other flu-like symptoms.

Even though oxycodone withdrawal is not usually fatal, it is incredibly uncomfortable. Snorting oxycodone increases the risk of addiction to the drug because of the more intense effects and rewarding sensation that reinforces continued use.

Some signs that someone may be addicted to oxycodone can include:. Athens, Greece. Andover, MA. Boston, MA. Wakefield, MA. Quincy, MA. Canton, MA. Ashby, MA. Falmouth, MA. Ottawa, ON. Baldwinville, MA.

Bethlehem, CT. Calverton, NY. New York City, NY. Waymart, PA. Call A treatment facility paid to have their center promoted here.

Learn more about how to be featured in a paid listing. Calls to numbers on a specific treatment center listing will be routed to that treatment center. Chats will be received and answered by one of treatment providers listed below, each of which is a paid advertiser:. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Inclusion Criteria: Participants have given written informed consent to participate.

Female or male participants, aged 18 years to 55 years inclusive at the time of the Enrollment Visit. Body mass index between 20 kilograms per square meter and 32 kilograms per square meter inclusive, with a minimum body weight of 55 kilograms.

Participants must be in good health as determined by the medical history, physical and laboratory examinations and must not show any clinically significant findings as determined by lead electrocardiogram ECG , vital signs pulse rate, respiratory rate, systolic and diastolic blood pressure , oxygen saturation, body temperature, and safety laboratory parameters hematology, clinical chemistry, clotting, and urinalysis.

Female participants of childbearing potential must agree to use one of the acceptable contraceptive regimens listed below from at least 15 days prior to the first administration of IMP until at least 30 days after the last administration of IMP.

For female participants of childbearing potential: Combined estrogen- and progestogen-containing hormonal contraception. Progestogen-only hormonal contraception associated with inhibition of ovulation.

An intra-uterine device hormone-free. An intra-uterine hormone releasing system. Bilateral tubal occlusion. Double barrier methods i. Current opioid users who have used opioids for recreational non-therapeutic purposes, i.

Participants who have intranasally insufflated drugs for recreational non-therapeutic purposes at least 3 times in the last 12 months before the Enrollment Visit. Exclusion Criteria: Resting pulse rate below 50 beats per minute or above beats per minute.

Resting systolic blood pressure below 90 mmHg or above mmHg. Resting diastolic blood pressure above 90 mmHg. Prolongation of the corrected QT interval Fridericia , i. Evidence for thyroid disease based on clinical and safety laboratory findings, including thyroid-stimulating hormone TSH. Any laboratory value from blood samples taken at the Enrollment Visit meeting the following criteria: Out-of-reference range value for serum creatinine or clotting parameter prothrombin international normalized ratio.

Exclusion range met for urinalysis or alanine transaminase, aspartate transaminase, alkaline phosphatase, total bilirubin, glucose fasted , gamma-glutamyl transferase, lactate dehydrogenase, potassium, total protein, sodium, calcium, hemoglobin, hematocrit, white blood cell count, or platelets. Out-of-reference range value for any other safety laboratory parameter that is judged by the investigator to be clinically relevant. Positive or missing virus serology test for human immunodeficiency virus Type 1 or Type 2 antibodies and antigen, hepatitis B surface antigen, hepatitis B core antigen antibodies, or hepatitis C virus antibodies.

For female participants: positive or missing pregnancy test. Participant received an IMP or an investigational medical device in another clinical trial less than 30 days before the Enrollment Visit.

Depending on the nature of the previous IMP or investigational medical device, a longer washout may be needed. Diseases or conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.

History of orthostatic hypotension. Known history of or at risk of seizures i. Any hint of chronic drug abuse, e.